Impax Laboratories, Inc.
IPXL today announced that its Board of Directors has appointed G.
Frederick Wilkinson as Impax's President and Chief Executive Officer effective
April 29, 2014. Mr. Wilkinson, who previously served as President, Actavis
Global Research and Development at Actavis plc succeeds Larry Hsu, Ph.D. who
is retiring.
"A long-time industry leader, Fred's extensive experience in managing generic,
brand, R&D, and regulatory and compliance activities, together with his track
record in driving change, delivering growth, advancing pipeline products and
driving innovation, make him the perfect candidate for this role," said Robert
L. Burr, Chairman of Impax Laboratories, Inc. "I have every confidence that
Fred's vision and passion will translate into remarkable success for Impax.
The Board would like to thank Dr. Hsu for his incredible dedication and
commitment over the last 18 years and for positioning the Company for its next
phase of growth."
Mr. Wilkinson said, "I am grateful to Dr. Hsu and the Board for the privilege
to lead the future direction of the Company and reinforce a quality-first
culture. This is a great company, with a strong balance sheet, experienced
business team and multiple product opportunities. I look forward to building
on Impax's success."
Mr. Wilkinson, 57, joined Watson Pharmaceuticals Inc. (now Actavis) as
Executive Vice President, Global Brands in September 2009. Prior to joining
Watson, he was President and Chief Operating Officer of Duramed
Pharmaceuticals, Inc., the proprietary products subsidiary of Barr
Pharmaceuticals Inc. from 2006 to 2009. Prior to joining Duramed
Pharmaceuticals, Inc., he was President and Chief Executive Officer of
Columbia Laboratories, Inc. from 2001 to 2006. From 1996 to 2001, Mr.
Wilkinson was Senior Vice President and Chief Operating Officer of Watson.
Prior to joining Watson, he spent 16 years at Sandoz in numerous senior
management positions of increasing responsibility. Mr. Wilkinson received a
M.B.A. from Capital University in 1984 and a B.S. in Pharmacy from Ohio
Northern University in 1979.
Impax Laboratories will release its first quarter 2014 financial results after
the close of the U.S. financial markets on May 1, 2014. Mr. Wilkinson will
participate in the conference call with the investment community on May 1 at
4:30 p.m., Eastern Time.
Today's announcement concludes a transition process that began in 2013 when
Dr. Hsu first announced his decision to retire. Dr. Hsu will continue to serve
on the Impax Board.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a technology based specialty
pharmaceutical company applying its formulation expertise and drug delivery
technology to the development of controlled-release and specialty generics in
addition to the development of central nervous system disorder branded
products. Impax markets its generic products through its Global
Pharmaceuticals division and markets its branded products through the Impax
Pharmaceuticals division. Additionally, where strategically appropriate, Impax
develops marketing partnerships to fully leverage its technology platform and
pursues partnership opportunities that offer alternative dosage form
technologies, such as injectables, nasal sprays, inhalers, patches, creams and
ointments. For more information, please visit the Company's Web site at:
www.impaxlabs.com.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsManagement
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in